Medicine and the Media : Thalidomide—the drama continues  

Oleh:

Tuffs, Annette

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: British Medical Journal (keterangan: ada di Proquest) vol. 335 no. 7630 (Dec. 2007), page 1125.

Ketersediaan

Perpustakaan FK Nomor Panggil: B16.K.2007.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

When a drug causes adverse effects, do the people affected need the help of media pressure to support their claims to compensation? This is certainly true in the case of thalidomide, Germany's worst ever pharmaceutical tragedy, which started in 1957. Its 2700 survivors in Germany were almost forgotten until a two part television drama named after the drug's German trade name, Contergan, was broadcast during prime time on 7 and 8 November, highlighting their fate and reaching millions of people. Several accompanying documentaries, interviews, and talk shows have provided additional information. More than 50 years later, Sebastian Wirtz, chief executive officer of the pharmaceutical firm Grünenthal (the German manufacturer of thalidomide) and grandson of its founder, was the first member of his family prepared to meet people affected by thalidomide, which caused severe malformations in more than 12 000 newborns worldwide. Wirtz admitted a "moral responsibility, but no moral fault . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali